T. R. J. Evans

589 total citations
25 papers, 467 citations indexed

About

T. R. J. Evans is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, T. R. J. Evans has authored 25 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in T. R. J. Evans's work include Cancer Treatment and Pharmacology (6 papers), Cancer Genomics and Diagnostics (4 papers) and Histone Deacetylase Inhibitors Research (3 papers). T. R. J. Evans is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Cancer Genomics and Diagnostics (4 papers) and Histone Deacetylase Inhibitors Research (3 papers). T. R. J. Evans collaborates with scholars based in United Kingdom, United States and France. T. R. J. Evans's co-authors include Johann S. de Bono, R. Molife, Alan Anthoney, I Bone, Natasha Aziz, Glenn Michelson, Debashis Sarker, Ian Judson, Sharianne G. Louie and Carla Heise and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Hepatology.

In The Last Decade

T. R. J. Evans

24 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. R. J. Evans United Kingdom 11 216 134 106 87 44 25 467
Alba Mineo Italy 11 207 1.0× 111 0.8× 99 0.9× 48 0.6× 42 1.0× 13 445
Emel Yaman Türkiye 11 112 0.5× 160 1.2× 47 0.4× 131 1.5× 20 0.5× 41 419
Qinglong Hu United States 7 213 1.0× 111 0.8× 75 0.7× 44 0.5× 72 1.6× 10 456
C Henkle United States 7 194 0.9× 184 1.4× 105 1.0× 173 2.0× 35 0.8× 8 707
Salina Tsai United States 7 492 2.3× 175 1.3× 134 1.3× 170 2.0× 54 1.2× 9 747
Hiroyuki Yamaoka Japan 13 69 0.3× 146 1.1× 81 0.8× 103 1.2× 42 1.0× 37 471
Sharon Space United States 2 179 0.8× 194 1.4× 128 1.2× 86 1.0× 40 0.9× 5 464
D. C. Rowlands United Kingdom 14 120 0.6× 211 1.6× 82 0.8× 99 1.1× 37 0.8× 26 469
Eva Szentgyörgyi Canada 11 290 1.3× 346 2.6× 179 1.7× 145 1.7× 29 0.7× 28 693
Mina Waraya Japan 15 279 1.3× 196 1.5× 124 1.2× 79 0.9× 44 1.0× 30 514

Countries citing papers authored by T. R. J. Evans

Since Specialization
Citations

This map shows the geographic impact of T. R. J. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. R. J. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. R. J. Evans more than expected).

Fields of papers citing papers by T. R. J. Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. R. J. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. R. J. Evans. The network helps show where T. R. J. Evans may publish in the future.

Co-authorship network of co-authors of T. R. J. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of T. R. J. Evans. A scholar is included among the top collaborators of T. R. J. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. R. J. Evans. T. R. J. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coveler, Andrew L., Kristen K. Ciombor, J. Graham, et al.. (2022). 354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302). Annals of Oncology. 33. S697–S698. 2 indexed citations
2.
3.
McNamara, Mairéad G., Daniel H. Palmer, Harpreet Wasan, et al.. (2018). A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08). Annals of Oncology. 29. viii259–viii259. 7 indexed citations
4.
Venugopal, B., Ahmad Awada, T. R. J. Evans, et al.. (2015). A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 76(4). 785–792. 14 indexed citations
5.
Roxburgh, Patricia, L Rhoda Molife, Anubha Gupta, et al.. (2013). A phase 1 study of oral rucaparib in combination with carboplatin. European Journal of Cancer. 49. 2 indexed citations
6.
Gan, Hui, Noelia Nebot, J.C. Soria, et al.. (2012). 613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 189–189. 3 indexed citations
7.
Ratain, Mark J., G. K. Schwartz, Amit M. Oza, et al.. (2011). Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 29(15_suppl). 3079–3079. 18 indexed citations
8.
Baird, Richard D., B. Venugopal, Montserrat Blanco-Codesido, et al.. (2011). A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.. Journal of Clinical Oncology. 29(15_suppl). 3024–3024. 1 indexed citations
9.
Macpherson, Iain R., D. Bissett, Russell Petty, et al.. (2011). A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer.. Journal of Clinical Oncology. 29(15_suppl). 3063–3063. 9 indexed citations
10.
Schwartz, G. K., Robert G. Maki, Mark J. Ratain, et al.. (2011). Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. Journal of Clinical Oncology. 29(15_suppl). 10000–10000. 14 indexed citations
11.
Steele, Nicola, Jane A. Plumb, Laura Vidal, et al.. (2010). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology. 67(6). 1273–1279. 45 indexed citations
12.
Lawitz, Eric, R. Gary Rozier, Thomas Marbury, et al.. (2009). 622 SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS. Journal of Hepatology. 50. S229–S229. 5 indexed citations
13.
Sarker, Debashis, R. Molife, T. R. J. Evans, et al.. (2008). A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(7). 2075–2081. 117 indexed citations
14.
Glen, Hilary, David S. Boss, T. R. J. Evans, et al.. (2007). A phase I dose finding study of E7080 in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 25(18_suppl). 14073–14073. 7 indexed citations
15.
Evans, T. R. J., Annick D. Van den Abbeele, Iain McPherson, et al.. (2005). Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3034–3034. 26 indexed citations
16.
Plumb, Jane A., Nicola Steele, T. R. J. Evans, et al.. (2004). 58 Pharmacodynamic responses to a novel histone deacetylase inhibitor, PXD101, in mice and humans. European Journal of Cancer Supplements. 2(8). 21–21. 13 indexed citations
17.
Bono, Johann S. de, Angus Dalgleish, J Carmichael, et al.. (2000). Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide.. PubMed. 6(2). 397–405. 45 indexed citations
18.
Anthoney, Alan, I Bone, & T. R. J. Evans. (2000). Inflammatory demyelinating polyneuropathy: A complication of immunotherapy in malignant melanoma. Annals of Oncology. 11(9). 1197–1200. 25 indexed citations
19.
Evans, T. R. J., et al.. (1998). Septic arthritis of the knee following anterior cruciate ligament reconstruction: results of a survey of sports medicine fellowship directors. Arthroscopy The Journal of Arthroscopic and Related Surgery. 14(7). 717–725. 83 indexed citations
20.
Yacoub, M, et al.. (1990). CARDIAC TRANSPLANTATION FOR DOXORUBICIN‐INDUCED CARDIOMYOPATHY IN ACUTE MYELOID LEUKAEMIA. British Journal of Haematology. 74(4). 541–541. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alba Mineo Breakdown of academic impact, for papers by Emel Yaman Breakdown of academic impact, for papers by Qinglong Hu Breakdown of academic impact, for papers by C Henkle Breakdown of academic impact, for papers by Salina Tsai Breakdown of academic impact, for papers by Hiroyuki Yamaoka Breakdown of academic impact, for papers by Sharon Space Breakdown of academic impact, for papers by D. C. Rowlands Breakdown of academic impact, for papers by Eva Szentgyörgyi Breakdown of academic impact, for papers by Mina Waraya
Rankless by CCL
2026